Vaginitis Market

Market Overview:

The 7 major vaginitis markets reached a value of US$ 2.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.2 Billion by 2034, exhibiting a growth rate (CAGR) of 3.49% during 2024-2034.

The vaginitis market has been comprehensively analyzed in IMARC's new report titled "Vaginitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Vaginitis refers to inflammation or irritation of the vagina, which is the muscular canal in the female reproductive organ that connects the uterus to the external genitalia. It is a common condition that can affect women of all ages. Some usual symptoms of the ailment may include abnormal vaginal discharge with an unusual color or consistency, itching, irritation, redness, pain or discomfort while sexual intercourse, a burning sensation during urination, etc. In severe cases, women suffering from this disorder might also experience swelling or uncomfortableness in the external genital area (vulva). The diagnosis of vaginitis typically involves a combination of medical history, laboratory tests, and a physical examination. A microscopic investigation of vaginal discharge is often performed to determine the cause of underlying indications or identify the presence of bacteria, yeast cells, or trichomonas organisms. If an allergic reaction or sensitivity is suspected, the doctor may recommend additional studies, such as patch testing or skin prick tests, to evaluate specific allergens or irritants. Additionally, a pelvic examination is also conducted to visually inspect the external genital area and vagina for any signs of inflammation, discharge, or several other abnormalities.

The increasing cases of bacterial vaginosis, which cause an imbalance in the normal vaginal flora that can lead to an overgrowth of harmful bacteria, are primarily driving the vaginitis market. In addition to this, the escalating incidences of yeast infections due to various factors, such as weakened immune systems, hormonal changes, uncontrolled diabetes, wearing tight or damp clothing, etc., are creating a positive outlook for the market. Moreover, the widespread adoption of antibiotic drugs, including metronidazole and clindamycin, since they can inhibit the production of bacterial toxins associated with the condition, thereby reducing inflammation and promoting healing, is further bolstering the market growth. Additionally, the inflating application of antifungal suppositories that deliver the medication directly to the vagina is acting as another significant growth-inducing factor. This targeted approach helps to concentrate the therapeutic agent at the site of infection, enhancing its effectiveness. Furthermore, the emerging popularity of hormone replacement therapy, which can replenish estrogen levels and restore vaginal lubrication to reduce discomfort, itching, and pain in patients, is expected to drive the vaginitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the vaginitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for vaginitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the vaginitis market in any manner.

Key Highlights:

• Vaginitis is prevalent in adult women but uncommon in prepubertal girls.
• Bacterial vaginosis accounts for 40-50% of vaginitis cases, followed by vaginal candidiasis (20-25%) and trichomoniasis (15-20%).
• Bacterial vaginosis is the most frequent vaginal infection among U.S. women of reproductive age.
• Every year, around 7.4 million new cases of bacterial vaginosis are reported.
• In the United States, up to 16% of pregnant women develop bacterial vaginosis.
• Female prisoners and commercial sex workers have a 50-60% prevalence rate.

Drugs:

VIVJOA (oteseconazole) is a prescription medication used to minimize the frequency of recurring vaginal yeast infections (recurrent vulvovaginal candidiasis, RVVC) in females who have a history of RVVC but are not pregnant or unable to become pregnant. The drug is a highly selective inhibitor of fungal CYP51 which works by inhibiting fungal growth.

Vagifem is a vaginal insert containing estradiol (an estrogen hormone) used to treat moderate to severe menopausal symptoms in and around the vagina. Vagifem is inserted directly into the vagina, where the person is experiencing changes, to assist in restoring estrogen lost during menopause.

Brexafemme (ibrexafungerp) is a novel oral glucan synthase inhibitor that has a wide range of efficacy, including against developing resistance threats. Its method of action is comparable to echinocandins, with a fungicidal effect against yeast (meaning it kills the fungus), versus fluconazole, which is fungistatic (meaning it inhibits fungal growth).

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the vaginitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the vaginitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current vaginitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the vaginitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the vaginitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the vaginitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of vaginitis across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of vaginitis by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of vaginitis by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with vaginitis across the seven major markets?
• What is the size of the vaginitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of vaginitis?
• What will be the growth rate of patients across the seven major markets?
   

Vaginitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for vaginitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the vaginitis market?
• What are the key regulatory events related to the vaginitis market?
• What is the structure of clinical trial landscape by status related to the vaginitis market?
• What is the structure of clinical trial landscape by phase related to the vaginitis market?
• What is the structure of clinical trial landscape by route of administration related to the vaginitis market?